Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC).

Next Previous
Trial Profile

A Phase 1/2 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elesclomol (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Synta Pharmaceuticals

Most Recent Events

  • 31 Jan 2014 According to ClinicalTrials.gov record trial status changed from suspended to completed.
  • 27 Feb 2009 Status changed from active, no longer recruiting to discontinued. The reasons for the decision to suspend this trial have been reported in a Synta Pharmaceuticals media release.
  • 16 Dec 2008 New source identified and integrated (ClinicalTrials.gov record NCT00808418).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top